Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17789604 | 0.93 | KDM4E (0.47) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL9069963 | 0.91 | KDM4E (0.49) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL31347123 | 0.88 | ALDH1A1 (0.47) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL2718011 | 0.88 | ALDH1A1 (0.47) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL25189286 | 0.86 | PTPN11 (0.54) | KDM4EALDH1A1LMNATDP1POLB | |
| SCHEMBL8909201 | 0.84 | KDM4E (0.42) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL17987756 | 0.84 | KDM4E (0.34) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL9199044 | 0.82 | CA12 (0.55) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL26228810 | 0.82 | PTPN11 (0.49) | KDM4EALDH1A1LMNATDP1POLB | |
| SCHEMBL13350408 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104409-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | WO | disclosed |
| EP-4741400-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4626489-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024116053-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | MEDIMMUNE LIMITED (GB) | 2022-12-13 | — | — | US | disclosed |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | MC SAF (FR) | 2022-03-22 | — | — | US | disclosed |
| EP-3825304-A1 | ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | Mc SAF (FR) | 2021-05-26 | — | — | EP | disclosed |
| US-20210079023-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | MEDIMMUNE LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| EP-3521314-B1 | ANTIBODY-DRUG CONJUGATES AND USE THEREOF IN THERAPY | MC SAF (FR) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019197602-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | MEDIMMUNE LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
| US-10307488-B2 | Antibody-drug conjugates and the use of same in therapy | UNIVERSITE FRANCOIS RABELAIS (FR) | 2019-06-04 | — | — | US | disclosed |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | MC SAF (FR) | 2016-06-02 | — | — | US | disclosed |
| WO-2015004400-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | UNIVERSITE FRANCOIS RABELAIS (FR) | 2015-01-15 | — | — | WO | disclosed |
| WO-2010070232-A1 | NOVEL RARE EARTH ELEMENT CRYPTATES INCLUDING A TETRAAZATRIPHENYLENE UNIT | CIS BIO INTERNATIONAL (FR) | 2010-06-24 | — | — | WO | disclosed |
| EP-1290448-B1 | RARE EARTH METAL CRYPTATES SHOWING REDUCED FLUORESCENCE QUENCHING | CIS BIO INT (FR) | 2007-11-07 | — | — | EP | disclosed |
| EP-1290448-B1 | RARE EARTH METAL CRYPTATES SHOWING REDUCED FLUORESCENCE QUENCHING | CIS BIO INT (FR) | 2007-11-07 | — | — | EP | disclosed |
| US-7087384-B2 | Rare earth metal cryptates which are not very sensitive to the fluorescence quenching | CIS BIO INTERNATIONAL (FR) | 2006-08-08 | — | — | US | disclosed |
| US-20040092726-A1 | Novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching | CIS BIO INTERNATIONAL (FR) | 2004-05-13 | — | — | US | disclosed |
| EP-1290448-A2 | RARE EARTH METAL CRYPTATES SHOWING REDUCED FLUORESCENCE QUENCHING | CIS BIO INTERNATIONAL (FR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096877-A2 | RARE EARTH METAL CRYPTATES SHOWING REDUCED FLUORESCENCE QUENCHING | CIS BIO INTERNATIONAL (FR) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | PBRM1, HDAC6, NPM1 | KDM4E 1557/4885ALDH1A1 1297/4885CA12 861/4885 |
| US-20210079023-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | PBRM1, HDAC6, NPM1 | KDM4E 1557/4885ALDH1A1 1297/4885CA12 861/4885 |
| US-10307488-B2 | Antibody-drug conjugates and the use of same in therapy | CD47, TNFRSF9, VSIG8 | KDM4E 3028/4885ALDH1A1 1271/4885CA12 689/4885 |
| US-20040092726-A1 | Novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching | SQOR, MCU, NDUFS4 | KDM4E 3781/4885ALDH1A1 2119/4885CA12 206/4885 |
| US-20160151515-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND THE USE OF SAME IN THERAPY | CD47, TNFRSF9, VSIG8 | KDM4E 3225/4885ALDH1A1 1572/4885CA12 921/4885 |
| US-11278627-B2 | Antibody-drug conjugates and the use of same in therapy | CD47, TNFRSF9, VSIG8 | KDM4E 3028/4885ALDH1A1 1271/4885CA12 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.